Point of Care Diagnostics Market Size & Forecast Report 2032
Point of Care Diagnostics Market Overview, Global Size | 2032

Point of Care (PoC) Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Product; By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays); By End-Use; By Region; Segment Forecast, 2024 - 2032

  • Published Date:Jan-2024
  • Pages: 116
  • Format: PDF
  • Report ID: PM1099
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

The global point of care (PoC) diagnostics market was valued at USD 51.30 billion in 2023 and is expected to grow at a CAGR of 9.40% during the forecast period.

POC diagnostics refers to medical tests and devices that can be performed at or near the patient's location, providing rapid results and enabling immediate treatment decisions. This approach eliminates the need for samples to be sent to centralized laboratories, reducing turnaround time and improving patient outcomes. The growing demand for rapid and accurate diagnostic tests is due to the increasing prevalence of chronic diseases and the need for early detection. POC tests enable healthcare professionals to quickly diagnose and monitor conditions such as diabetes, cardiovascular diseases, infectious diseases, and cancer, leading to timely interventions and improved patient management.

Point of Care (PoC) Diagnostics Market Size

To Understand More About this Research: Request a Free Sample Report

There is a growing prevalence of target diseases such as diabetes, blood-related disorders, and lifestyle-borne diseases. The need for effective management and monitoring of these conditions has fueled the demand for POC diagnostics. These devices provide real-time diagnosis, allowing patients and healthcare providers to make timely and informed decisions regarding treatment and management plans.

Advancements in technology have played a crucial role in expanding the POC diagnostics market. Miniaturization of devices, the development of portable and handheld diagnostic tools, and the integrating of advanced technologies like biosensors and nanotechnology have made POC testing more accessible and user-friendly. These innovations have also reduced the cost of testing, making it more affordable for healthcare providers, especially in resource-limited settings.

The market has experienced a profound impact from the COVID-19 pandemic. The urgent need for rapid and widespread testing to identify and manage the virus has driven significant demand for POC diagnostic tests specifically designed for COVID-19. These tests, such as rapid antigen tests and portable PCR devices, have played a crucial role in quickly screening, diagnosing, and monitoring COVID-19 cases. They offer advantages like fast results, convenience, and the ability to be used outside of traditional laboratory settings. The pandemic has also accelerated the adoption of telehealth and remote patient monitoring, relying on POC diagnostics to track and manage COVID-19 patients remotely.

Point of Care (PoC) Diagnostic

For Specific Research Requirements: Request for Customized Report

Industry Dynamics

Point of Care Diagnostics Market : Growth Drivers

Rising prevalence of infectious diseases

The increasing prevalence of infectious diseases globally is a significant driver of the Point-of-Care (POC) diagnostics market. Diseases such as COVID-19, influenza, HIV, and tuberculosis are spreading rapidly, creating a heightened need for rapid and accurate diagnostic tests. POC diagnostics play a crucial role in early detection, timely treatment, and effective management of these diseases. By providing immediate results at the point of care, POC tests enable healthcare professionals to quickly identify infected individuals, initiate appropriate interventions, and prevent further transmission. This growing burden of infectious diseases has fueled the demand for POC diagnostics and will continue to drive market growth.

Technological advancements have played a pivotal role in the growth of POC diagnostics. Innovations such as the miniaturization of devices, the integration of biosensors and nanotechnology, and the development of portable and handheld testing systems have made POC diagnostics more accurate, user-friendly, and accessible. These advancements have also resulted in the creation of innovative POC tests capable of simultaneously detecting multiple diseases or biomarkers, enhancing the efficiency of diagnosis and treatment decision-making.

Furthermore, there is a growing emphasis on personalized medicine, where medical decisions and treatments are tailored to individual patients. POC diagnostics facilitate this approach by providing real-time patient data, enabling healthcare providers to customize treatment plans and monitor therapeutic responses. This shift towards personalized medicine improves patient outcomes, reduces healthcare costs, and enhances patient satisfaction.

There is a noticeable shift towards home healthcare as a preferred option for many patients, particularly among the elderly and individuals with chronic conditions. POC diagnostics facilitate this trend by enabling diagnostic tests to be performed outside of traditional healthcare settings, including in the comfort of one's home. This offers several advantages: convenience, reduced costs, and increased patient autonomy. POC user-friendly tests that provide accurate results enable patients to monitor their health conditions regularly without frequent visits to healthcare facilities. The COVID-19 pandemic has further accelerated this preference for home healthcare as individuals seek to minimize their exposure to healthcare settings. As a result, the demand for POC diagnostics has grown significantly, supporting the expansion of the market.

Report Segmentation

The market is primarily segmented based on product, platform, end-use, and region.

By Product

By Platform

By End-Use

By Region

  • Glucose Testing
  • Hb1Ac Testing
  • Coagulation
  • Fertility
  • Infectious Diseases
  • HIV
  • Clostridium Difficile
  • HBV
  • Pneumonia or Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV)
  • HPV
  • Influenza/Flu
  • HCV
  • MRSA
  • TB and Drug-Resistant TB
  • HSV
  • Others
  • Cardiac Markers
  • Thyroid Stimulating Hormone
  • Hematology
  • Primary Care Systems
  • Decentralized Clinical Chemistry
  • Feces
  • Lipid Testing
  • Cancer Marker
  • Blood Gas/Electrolytes
  • Ambulatory Chemistry
  • Drug Abuse Testing
  • Urinalysis
  • Lateral Flow Assays
  • Dipsticks
  • Microfluidics
  • Molecular Diagnostics
  • Immunoassays
  • Clinics
  • Physician Office
  • Pharmacy & Retail Clinics
  • Non-practice Clinics
  • Urgent Care Clinic
  • Hospitals
  • Home
  • Assisted Living Healthcare Facilities
  • Laboratory
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

By Product Analysis

Glucose testing segment accounted for the largest market share in 2022

The glucose testing segment is accounted for the largest share of the market. This dominance can be attributed to the increasing prevalence of diabetes and related conditions worldwide. According to the International Diabetes Federation (IDF), there were approximately 463 million diabetic patients in 2019, with projections indicating a rise to around 700 million by 2045. The growing number of diabetes cases has fueled the demand for POC diagnostics specifically designed for glucose testing.

The market segment has also benefited from technological advancements in diabetes diagnosis, enabling real-time and on-site testing. These innovations have enhanced the accuracy and efficiency of glucose testing at the point of care. Moreover, the rising popularity of wearable and portable glucose meters has further driven the adoption of these products. These devices offer rapid results, ease of use, and lower operational costs, making them attractive options for patients and healthcare providers.

By End-Use Analysis

Clinics segment dominated the market in largest revenue shares in 2022

The clinics segment dominated the revenue share in the market. This can be attributed to the increasing establishment of PoC diagnostics laboratory centers within clinics, which has improved patient-centered medical care while reducing healthcare costs. These dedicated centers have led to the decentralization of healthcare services, resulting in enhanced patient outcomes.

Hospital outsourcing of testing procedures is a growing trend, leading to increased test efficiency and reduced labor costs. Hospitals leverage external resources for certain diagnostic tests, allowing them to focus on core functions and streamline operations. Additionally, favorable policies such as those outlined in Medicare and the CHIP Reauthorization Act have supported the growth of the PoC diagnostics industry segment. These policies have created a conducive environment for adopting and expanding PoC testing in various healthcare settings.

The home segment has experienced the fastest growth rate during the forecast period. This can be attributed to the increasing adoption of PoC testing among pediatric and geriatric populations. With declining birth rates in developing countries and improved access to medical care, the geriatric population is growing, leading to an increase in life expectancy. As a result, there is a greater prevalence of chronic conditions such as diabetes, memory loss, and lifestyle-related cardiac problems. PoC testing in home settings offers convenience and accessibility for these individuals, driving the segment's growth.

Regional Insights

North America holds the largest revenue shares of the market in 2022

The North American region holds the largest revenue share in the market. The growth in the North American region can be attributed to the presence of key players in the region has contributed to market expansion. Additionally, supportive government-sponsored research bodies such as the American Heart Association, International Diabetes Federation, and American Diabetes Association, along with dedicated academic institutions, have fostered advancements in PoC diagnostics. These collaborations have fueled research and development activities, leading to the introduction of innovative diagnostic solutions. Furthermore, the miniaturization of technology has played a crucial role in shaping the market's future. For instance, FUJIFILM SonoSite introduced Point-of-Care ultrasound systems for physicians nationwide, catering to the growing demand for portable and user-friendly diagnostic devices.

The Asia Pacific region is expected to witness the highest growth rate in the PoC diagnostics industry. This growth is driven by concerted efforts from local and international players to tap into the untapped potential of emerging countries with a large patient pool. Market players are expanding their presence and investing in research and development to meet the region's specific healthcare needs. For example, in January 2020, Mindray Medical introduced the TE7 ACE Point-of-Care ultrasound system designed for emergency and critical care situations, catering to the evolving healthcare landscape in the Asia Pacific region.

Market Key Players & Competitive Insight

Some of the major players operating in the global market include:

  • Abbott Laboratories
  • AccuBioTech
  • Becton, Dickinson and Company
  • Chembio Diagnostic Systems
  • Danaher Corporation
  • EKF Diagnostics
  • Instrumentation Laboratory Company
  • Johnson & Johnson
  • Nova Biomedical
  • PTS Diagnostics
  • Quidel Corporation
  • Roche Diagnostics
  • Sekisui Diagnostics
  • Siemens Healthineers
  • Trinity Biotech

Recent Developments

  • In November 2022, LumiraDx Healthcare has launched its high-sensitivity C-Reactive Protein (CRP) point-of-care (POC) antigen test in India. This POC CRP test is designed to be used in various clinical settings and aims to contribute to the reduction of unnecessary antibiotic prescribing, which is a significant factor in the development of antimicrobial resistance (AMR).
  • In January 2022, Roche has launched its Cobas Pulse System in certain countries where it has received the CE Mark certification. The Cobas Pulse System represents the latest advancement in Roche Diagnostics' connected point-of-care solutions for professional blood glucose management.

Point of Care (PoC) Diagnostics Market Report Scope

Report Attributes

Details

Market size value in 2024

USD 56.06 billion

Revenue forecast in 2032

USD 115.44 billion

CAGR

9.40% from 2024 – 2032

Base year

2023

Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

By Product, By Platform, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Customization

Report customization as per your requirements with respect to countries, region and segmentation.

FAQ's

The global point of care (PoC) diagnostics market size is expected to reach USD 115.44 billion by 2032.

Key players in the point of care (poc) diagnostics market are Siemens Healthineers, Roche Diagnostics, Chembio Diagnostic Systems, Johnson & Johnson.

North American contribute notably towards the global point of care (poc) diagnostics market.

The global point of care (PoC) diagnostics market is expected to grow at a CAGR of 9.4% during the forecast period.

The point of care (poc) diagnostics market report covering key segments are product, platform, end-use, and region.